| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
48 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
2 |
| Net Income (TTM) (Millions $) |
-1 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nuo Therapeutics, Inc. was a biopharmaceutical company that focused on developing and commercializing advanced wound care products. The company aimed to provide innovative solutions for the treatment of chronic and acute wounds, including diabetic foot ulcers.
Nuo Therapeutics developed a proprietary platform technology called Aurix, which utilized the patient's own blood to create a platelet and plasma-based therapy. This therapy was designed to promote wound healing and reduce inflammation, offering a potential alternative to traditional wound care approaches.
However, it is worth noting that as of my last knowledge update in 2021, Nuo Therapeutics, Inc. is no longer in operation. The company filed for bankruptcy and its assets were acquired by MiMedx Group, Inc. in 201
|
%